![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPAG17 |
Gene summary for SPAG17 |
![]() |
Gene information | Species | Human | Gene symbol | SPAG17 | Gene ID | 200162 |
Gene name | sperm associated antigen 17 | |
Gene Alias | CT143 | |
Cytomap | 1p12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q6Q759 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200162 | SPAG17 | PTC06 | Human | Thyroid | PTC | 4.17e-03 | 1.36e-01 | 0.2057 |
200162 | SPAG17 | ATC13 | Human | Thyroid | ATC | 1.50e-35 | 6.29e-01 | 0.34 |
200162 | SPAG17 | ATC5 | Human | Thyroid | ATC | 1.46e-39 | 6.82e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG17 | SNV | Missense_Mutation | novel | c.389N>C | p.Lys130Thr | p.K130T | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | rs750605549 | c.1603G>A | p.Ala535Thr | p.A535T | Q6Q759 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-BS-A0V4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | c.5604N>A | p.Phe1868Leu | p.F1868L | Q6Q759 | protein_coding | tolerated(0.68) | benign(0.009) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPAG17 | SNV | Missense_Mutation | novel | c.1744N>G | p.Met582Val | p.M582V | Q6Q759 | protein_coding | deleterious(0.04) | benign(0.199) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.236N>C | p.Glu79Ala | p.E79A | Q6Q759 | protein_coding | tolerated(0.09) | benign(0.199) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SPAG17 | SNV | Missense_Mutation | rs762885045 | c.739N>A | p.Val247Met | p.V247M | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.2473C>A | p.Pro825Thr | p.P825T | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | rs764604542 | c.2826A>C | p.Glu942Asp | p.E942D | Q6Q759 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.5875N>G | p.Phe1959Val | p.F1959V | Q6Q759 | protein_coding | tolerated(0.5) | benign(0.006) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.2432N>G | p.Tyr811Cys | p.Y811C | Q6Q759 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |